By jurisdiction
European Union (EMA)
Every compound we track that has a recorded status under European Union (EMA). Tap a name for the full picture, including the U.S. status and primary sources.
| Compound | Status here | Note |
|---|---|---|
| BPC-157 | Restricted | No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Cagrilintide | Restricted | No EU marketing authorisation; not on EMA's August 2026 list of applications under CHMP evaluation; sale as a medicine unlawful EU-wide, with enforcement at member-state level. |
| CJC-1295 | Restricted | No EU marketing authorisation; absent from the Union Register, so sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Emideltide (DSIP) | Restricted | No EU marketing authorisation for emideltide (DSIP); sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Epitalon | Restricted | No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| GHK-Cu | Restricted | No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Ipamorelin | Restricted | No EU marketing authorisation; absent from the Union Register, so sale as a medicine is unlawful EU-wide, with enforcement at member-state level. |
| KPV | Restricted | No EU marketing authorisation; not found in EMA's centralised medicines database, so sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Melanotan II | Restricted | No EU marketing authorisation - no melanotan II entry in EMA's centrally authorised medicines database; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| MOTS-c | Restricted | No EU marketing authorisation in the Union Register; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| NAD+ | Restricted | No EU marketing authorisation; injectable NAD+ cannot be marketed as a medicine EU-wide, with enforcement handled at member-state level; oral NAD+ circulates under food-supplement law. |
| Retatrutide | Restricted | No EU marketing authorisation and no application under CHMP evaluation as of August 2026; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Selank | Restricted | No EU marketing authorisation; Selank does not appear in the Union Register, so sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Semaglutide (compounded) | Restricted | Centrally authorised prescription-only medicine; compounded versions hold no EU marketing authorisation, with enforcement against unlicensed supply handled at member-state level. |
| Semax | Restricted | No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Sermorelin | Restricted | No centralised EU marketing authorisation (absent from the Union Register); sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| TB-500 (Thymosin Beta-4) | Restricted | No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Thymosin Alpha-1 | Restricted | No EU-wide EMA marketing authorisation - thymalfasin holds only an orphan designation (EU/3/02/110) - and is reported as nationally authorised on prescription in Italy as Zadaxin. |
| Tirzepatide (compounded) | Restricted | Licensed prescription-only medicine EU-wide (Mounjaro, authorised 2022); unauthorised versions cannot be marketed, with pharmacy compounding exemptions and enforcement handled at member-state level. |